
    
      Patients will be randomized 1:1 to receive docetaxel or hormone therapy (abiraterone or
      enzalutamide based on previous treatment).

      Docetaxel (standard) will be administered for 10 cycles (maximum).

      Hormone therapy (experimental) will be administered until progression or unacceptable
      toxicity.
    
  